Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts

Project Information

IMMUcan

Grant agreement ID: 821558

DOI 10.3030/821558

EC signature date 23 April 2019

Start date 1 March 2019

End date 31 August 2025

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 36 331 304,25

EU contribution € 17 830 000,00

Coordinated by

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
Belgium

Deliverables

Documents, reports (3)

Independent boards (EAB and SAB) up and constituted

Report on the composition of these boards.

Policy for third party access and use of project results

On month 1, it will be an agreement on the key principles regarding 3rd party access allowing to discuss contract with non-EORTC groups. The full policy will be available by month 6.

Leaflet in lay language

Leaflet explaining the project in lay language.

Other (1)

First newsletter circulated

First newsletter

Publications

Peer reviewed articles (2)

Yes, IMMUcan! Unraveling the human tumor microenvironment

Author(s): Henoch Hong, Robin Liechti, Marie Morfouace
Published in: Immuno-Oncology Insights, Issue 2021; 2(5),, 2021, Page(s) 301–309, ISSN 2059-7800
Publisher: BioInsights Publishing Ltd
DOI: 10.18609/ioi.2021.038

Meta-analysis of human cancer single cell RNA-seq datasets using the IMMUcan database.

Author(s): Jordi Camps; Floriane Noël; Robin Liechti; Lucile Massenet-Regad; Sidwell Rigade; Lou Götz; Caroline Hoffmann; Elise Amblard; Melissa Saichi; Mahmoud M. Ibrahim; Jack Pollard; Jasna Medvedovic; Helge G. Roider; Vassili Soumelis
Published in: Cancer Research, 2023, ISSN 1538-7445
Publisher: AACR
DOI: 10.1158/0008-5472.can-22-0074